

**Wednesday, 16 October 2019**
**Educational training day**

<b>Start time</b>	<b>Topic</b>	<b>Speaker</b>	<b>Abstract</b>
8:30	Arrival and refreshments		
9:00	Welcome and opening remarks	Pontiano Kaleebu	
	<b>Viral Escape &amp; Transmission</b>	<b>Pontiano Kaleebu and John Mellors</b>	
9:05	Presentation: Viral Escape	Monique Nijhuis	
9:30	Discussion		
9:40	Presentation: Transmission of resistance	Michael Jordan	
10:05	Discussion		
10:15	Presentation: Basic principles of phylogeny and transmission networks	Tulio de Oliveira	
10:40	Discussion		
10:50	Refreshment break		
	<b>Programmatic Treatment &amp; Viral Suppression</b>	<b>Gillian Hunt and Douglas Richman</b>	
11:20	Introduction: Goals of programmatic treatment	Elliot Raizes	
11:30	Presentation: HIV suppression: How well are we doing	Lucas Hermans	
11:50	Presentation: What should be done to optimise viral suppression?	Michelle Moorhouse	
12:10	Round Table Viral suppression rates	Douglas Richman and Francois Venter	
12:30	Lunch		
	<b>Clinical Management of HIV Drug Resistance</b>	<b>Carole Wallis and Annemarie Wensing</b>	
13:30	Presentation: Benefits and Pitfalls of resistance testing	Carole Wallis	
13:50	Discussion		
14:00	Case	Gert van Zyl	
14:30	Case study: Comparison of HIV-1 Viral Load and Drug Resistance Mutations between Cerebrospinal Fluid and Plasma in Patients with HIV and Cryptococcal Meningitis Co-infection in Botswana	Nomeiso Kelentse	13
14:35	Case discussion		
14:40	Case study: When Plasma Viral Load Does Not Answer the Question: 'Is the Patient Failing Therapy?'	Margaret Pascoe	17
14:45	Case discussion		
14:50	Refreshment break		
15:20	Presentation: HIV cure research	John Mellors	
15:40	Presentation: HIV post treatment control	Caroline Tiemessen	
16:00	Presentation: Understanding potential mechanism of cure by stem cell transplantation	Annemarie Wensing	
16:20	Discussion	John Mellors	
16:30	End		
17:30	Welcome reception function		

**Thursday, 17 October 2019**

Start time	Topic	Speaker	Abstract
8:30	Arrival and refreshments		
9:00	Welcome and opening remarks	Douglas Richman	
9:05	<b>Setting the scene</b>	Francois Venter	
	<b>Clinical Implications of Resistance</b>	<b>Douglas Richman</b>	
9:25	Accumulation of Integrase Strand-Transfer Inhibitor Resistance Mutations confers High Level Resistance to Dolutegravir in HIV-1 non-B Subtype Viruses from Patients Failing Raltegravir in Uganda	Emmanuel Ndashimye	23
9:35	Drug level testing as a strategy to determine eligibility for drug resistance testing in HIV-infected patients with failure on second-line ART	Lucas Hermans	48
9:45	Specific Guanosines in the HIV Leader RNA Direct Viral Genome Packaging	Chijioke Umunnakwe	26
9:55	A Simple Alternative for HIV Drug Resistance Genotyping: Laboratory Evaluation of the PANDAA qDx HIVDR RTI assay	Lara Noble	25
10:00	Simultaneous HIV-1 Quantification and Mutation Detection Using a Closed-Tube Assay	Robert Shafer	28
10:05	Discussion & Questions	Douglas Richman	
10:15	Mid-morning break		
	<b>Modelling Resistance &amp; PrEP and Resistance</b>	<b>John Mellors</b>	
10:45	Introduction of next speaker	John Mellors	
10:50	<b>Plenary: Modelling of ART and PrEP in sub-Saharan Africa</b>	Andrew Phillips	
11:10	Next-Generation Sequence Analysis in The Ring Study (IPM 027) Does Not Reveal Resistance Selection from Dapivirine Vaginal Ring Use for HIV-1 Infection Risk Reduction	Charles Craig	12
11:20	High level of HIV re-suppression following Intensive Adherence Counselling for adults on Protease Inhibitor- based second- line antiretroviral therapy at an urban HIV clinic in Kampala, Uganda	Nakibuuka Violet	27
11:30	Peripartum Virological Suppression and its Significant Implications for Elimination of Mother-To-Child Transmission of HIV in Resource-Constrained Settings of Eastern Cape, South Africa: Population Based Cohort Study	Oladele Adeniyi	5
11:40	HIV-1 Drug Resistance Surveillance among Parturient Women on Anti-retroviral Therapy in the Eastern Cape, South Africa: Implications for Elimination of Mother-To-Child Transmission	Oladele Adeniyi	6
11:50	Panel discussion		
12:10	Lunch		
	<b>Children and Adolescents</b>	<b>Gillian Hunt and Carole Wallis</b>	
13:15	Introduction of next speaker	Gillian Hunt	
13:20	<b>Plenary: HIV drug-resistance in children: Data demands use of different drugs</b>	Lisa Frenkel	
13:40	HIV Drug Resistance in samples from the routine early infant diagnosis programme	Iqra Barakzai	14
13:50	Resistance is common in paediatric patients failing ART in South Africa	Gillian Hunt	19
14:00	Drug Resistance Evolution Using Sanger and NGS in Kenyan Youth Living with HIV	Vlad Novitsky	24
14:10	The Presence of Archived HIV-1 Drug Resistance Mutations is Consistent with Advanced Clinical Stage and CD4-Nadir in Vertically-Infected Adolescents Failing Treatment	Joseph Fokam	35
14:20	Discussion		
14:30	Afternoon break		
15:00	Poster session	All	
16:00	Introduction of next speaker	Carole Wallis	
16:05	<b>Plenary: The role of NNRTIs in the treatment of children</b>	Louise Kuhn	
16:25	Debate: The role of raltegravir (against)	Leon Levin	
16:45	Debate: The role of raltegravir (for)	Lee Fairlie	
17:05	Closing remarks	Carole Wallis	
17:10	End		
18:00	Dinner at leisure		

**Friday, 18 October 2019**

Start time	Topic	Speaker	Abstract
8:30	Arrival and refreshments		
9:00	Welcome and opening remarks	Annemarie Wensing	
	<b>New and Long-Acting Drugs</b>	<b>Annemarie Wensing</b>	
9:05	<b>Plenary: Long-acting ARV formulations</b>	Charles Flexner	
9:25	Islatravir (MK-8591): A Versatile NRTTI for HIV treatment and prevention	Jay Grobler	
9:45	GS-6207: long acting HIV capsid inhibitor	Martin Rhee	
10:05	Discussion		
10:15	Mid-morning break		
10:45	Introduction of next speaker	Annemarie Wensing	
10:50	<b>Plenary: Long-acting antibodies for treatment</b>	Daniel Kuritzkes	
11:10	Introduction to next abstract presentation	Annemarie Wensing	
11:15	HIV Pseudo viremia from large defective cell population	Johannes Botha	15
11:20	Discussion		
11:30	Poster session	All	
12:30	Lunch		
	<b>Epidemiology of Resistance</b>	<b>Elliot Raizes</b>	
13:30	Introduction of next session	Elliot Raizes	
13:35	Pre-treatment HIV drug-resistance in Botswana	Simani Gaseitsiwe	50
13:45	Acquired antiretroviral drug resistance associated with low level viremia in South African patients on antiretroviral therapy	Adriaan Basson	45
13:55	Magnitude of Viral Load Does Not Correlate with Presence or Absence of HIV Drug Resistance at the Time of Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa	Suzanne McCluskey	32
14:05	Pretreatment HIV Drug Resistance in Cuba Patients During the Period 2009-2017: Results of the National Survey	Liuber Yans Machado Zaldivar	8
14:15	Discussion		
14:30	Afternoon break		
	<b>Third-line and complex treatment of patients</b>	<b>Francois Venter</b>	
15:00	Introduction of next session	Francois Venter	
15:05	Complex clinical cases in the management of virologic failure and HIV drug resistance	Mark Siedner	
15:30	South African 3rd Line Antiretroviral Database - 2019 Update	Ruth Lancaster	47
15:40	Third-Line Antiretroviral Therapy (ART) Program at Cecilia Makiwane Hospital, Eastern Cape, South Africa: Resistance Patterns and Temporal Data on Virological Suppression: 2019 Second Quarter Update	Dominique Kabengele Kayembe	51
15:50	How does our present knowledge of patterns of DR inform us as to the ideal approach to management of 1st and 2nd line failures in a public health setting	Elliot Raizes	
16:00	Panel discussion	Panel	
16:20	Closing remarks		
19:00	Awards Dinner		